A Novel Tri-Modal Viral–Ultrasound Gene-Delivery Therapy Protocol for Lysosomal Neurodegeneration via Stochastic Model Optimization with Uncertainty Quantification and Generalizability

Abstract

Lysosomal storage disorders (LSDs) are a class of more than 70 inherited metabolic diseases caused by deficient lysosomal enzyme activity, producing substrate accumulation, neuroinflammation, and progressive neuronal death. We focus on GM2 gangliosidosis (Tay-Sachs/Sandhoff), for which fewer than 100 new cases occur annually in the US and Europe combined, making prospective randomized trials both statistically underpowered and ethically untenable.

We present a 16-dimensional Itô stochastic differential equation (SDE) system, with generic form $dX_i = f_i(X,t)\,dt + \sigma_i X_i\,dW_i$, calibrated from 15 public genomic and proteomic datasets and integrated via the Milstein scheme ($N = 1{,}000$ realizations, $\Delta t = 0.1$ d). Tri-modal therapy — integrating AAV-T4 gene delivery, SP2 substrate reduction therapy, and focused ultrasound (FUS) blood–brain barrier modulation — reduces mean brain GM2 burden from 890 nmol/g to $180 \pm 35$ nmol/g (75.7%; 95% CI [74.2%, 77.2%]) versus 30–35% for SRT monotherapy and 40–50% for AAV monotherapy. Neuroinflammation suppression reaches 95–97% and Bayley-III motor/cognitive advantages are +49/+21 points at day 365.

Global Sobol analysis identifies BBB entry kinetics ($k_{T4,\text{entry}}$, $S_T = 0.909$) as the singular rate-limiting parameter, exceeding enzymatic degradation ($V_{\max,B}$) by 13.0-fold, establishing GM2 gangliosidosis as delivery-limited rather than enzyme-limited. Six-region neuroanatomical validation confirms uniform 80–89% GM2 reduction (CV = 3.7%). Modular substitution across nine LSDs reproduces consistent BBB-bottleneck dominance ($S_T = 0.82\text{–}0.91$) with ≈90% parameter reuse, establishing computational stochastic optimization as a translational strategy for ultra-rare diseases.

Why Monotherapy Is Insufficient: A Formal Bottleneck Analysis

Three mechanistically non-redundant rate-limiting steps must be addressed concurrently for meaningful substrate clearance. No mono- or bi-modal therapy closes all three simultaneously:

Only the tri-modal combination (SRT + AAV + FUS) simultaneously reduces synthesis, restores enzyme, and amplifies transport — yielding synergy index 1.47 and 95–97% neuroinflammation suppression by disrupting the microglial feedback loop (GM2 $> G_{th} = 500$ nmol/g).

GM2 Substrate Dynamics — All Treatment Arms

Figure 1. Brain GM2 burden (nmol g⁻¹) over 365 days across all treatment arms, $N = 1{,}000$ Milstein realizations. Shaded bands: 5th–95th percentile. Tri-modal (blue) achieves 75.7% substrate reduction (890 → 180 nmol/g) versus continuous rise in natural history (890 → 1,325 nmol/g). The strict NH < mono < bi < tri hierarchy is preserved at every time step.

Neuroinflammation & Bayley-III Clinical Outcomes

Figure 2. (A) Neuroinflammation index $I(t)$: tri-modal (blue) suppresses inflammation to physiological levels ($I \approx 0.05$) by day 250; untreated (red) plateaus at $I \approx 0.5$. (B) Bayley-III cognitive trajectories across all arms ($N = 1{,}000$). (C) Terminal motor/cognitive Bayley-III scores at day 365 — tri-modal achieves $\Delta = -8.6$ vs. natural history $\Delta = -44.8$.

Global Sobol Sensitivity Analysis

Figure 3. (A) Global Sobol indices ($N = 1{,}000$ Saltelli samples, 50 realizations each; 95% CI). $k_{T4,\text{entry}}$ dominates at $S_T = 0.909$, exceeding $V_{\max,B}$ by 13.0× (total-order) and 16.5× (first-order). (B) Terminal GM2 distribution under tri-modal therapy ($N = 1{,}000$): median = 147 nmol/g, mean = 188 nmol/g — far below the microglial activation threshold $G_0$.

The Sobol decomposition formalizes the delivery-limitation argument quantitatively: knowing $k_{T4,\text{entry}}$ alone reduces outcome variance by 90.9%, whereas knowing all other parameters simultaneously reduces it by only 9.1%. This is a direct consequence of Michaelis–Menten saturation ($G_B \gg K_{m,B}$) and holds robustly across the full Saltelli parameter space. The implication for program design is unambiguous: capsid engineering, intrathecal administration, and FUS-mediated opening represent the highest-leverage interventions — not enzyme optimization.

Six-Region Spatial Validation

Figure 4. GM2 reduction trajectories across six brain regions under tri-modal therapy ($N = 1{,}000$ per region). Frontal cortex and thalamus: 88%; temporal lobe: 84%; hippocampus: 86%; basal ganglia: 85%; cerebellum: 80% (lower AAV tropism). Spatial CV = 3.7% validates the lumped-compartment approximation used in the primary analysis.

Cross-Disease Generalizability — Nine Lysosomal Storage Disorders

Figure 5. (A) Terminal substrate reduction: tri-modal vs. untreated ($N = 1{,}000$). (B) Universal BBB bottleneck: $S_T(k_{T4,\text{entry}}) = 0.82\text{–}0.91$ across all nine disorders, independent of enzymatic substrate. (C) Bayley-III cognitive outcomes: treated vs. untreated for each disease.

$S_T = 0.82\text{–}0.91$ across all nine disorders, spanning heterogeneous enzymatic substrates (glycolipids, sphingomyelin, heparan sulfate, acid glucosidase), neuroanatomical vulnerability patterns, and Michaelis constants covering a two-fold range ($K_m = 260\text{–}380$ nmol/g). The universality of BBB-transport dominance points to a structural rather than disease-specific explanation: intravenous AAV penetrates the CNS at <1% efficiency in any disease context. ≈90% parameter reuse enables framework-wide generalization with only four disease-specific substitutions per new disorder.

Lysosomal Disorder Biology: From Gene Mutation to Neurodegeneration

Lysosomal storage disorders originate when inherited mutations abolish the activity of a single lysosomal hydrolase, converting the cell's primary degradation organelle into a substrate trap. The diagram below traces the full cascade from HEXA/HEXB gene variants — through enzymatic failure, lysosomal engorgement, ER stress, and microglial activation — to irreversible neurodegeneration, and contrasts it with the healthy equilibrium maintained by functional β-hexosaminidase.

Tri-Modal Therapy: How Each Modality Restores Homeostasis

Each therapeutic modality intercepts a distinct, non-redundant node in the pathomechanism cascade. SP2 suppresses GM2 biosynthesis upstream; AAV-T4 restores the missing enzyme downstream; FUS amplifies CNS delivery 10–100× by acoustically opening BBB tight junctions during a precisely timed 7-day window before anti-capsid IgG peaks. Only their concurrent application removes all three rate-limiting constraints simultaneously.

Multi-Modal Diagnostic Protocol & Severity Classification

Because GM2 gangliosidosis and related LSDs are ultra-rare and rapidly progressive in their infantile form, early accurate diagnosis is essential for treatment eligibility. The current standard combines newborn biochemical screening, confirmatory molecular genetics, neuroimaging for disease burden, and standardized functional assessment — each tier informing both diagnosis and severity staging for trial enrollment and outcome monitoring.

Disease Severity Classification

Severity is determined by residual enzyme activity, age of onset, GM2 substrate load (correlating with model parameter G_B,0), and rate of functional decline. Classification guides treatment urgency and defines the simulation's initial conditions.

Key Biomarker Reference Thresholds

The biomarkers below are used to stratify patients at baseline and track response to therapy in clinical studies. Plasma and CSF neurofilament light chain (NfL) are the most sensitive progression biomarkers; chitotriosidase reflects the neuroinflammatory burden modeled by $I(t)$ in the SDE system.

People

• Chandrajit Bajaj
• Kartheek Nekkanti